CareDx CDNA Reportable Segment — Research materials and clinical trials expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept cdna:ResearchMaterialsAndClinicalTrialsExpense.
The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about CareDx's reportable segment — research materials and clinical trials expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CareDx's reportable segment — research materials and clinical trials expense?
- CareDx (CDNA) reported reportable segment — research materials and clinical trials expense of $3.83M in Q1 2026.
- How has CareDx's reportable segment — research materials and clinical trials expense changed year-over-year?
- CareDx's reportable segment — research materials and clinical trials expense increased by 20.7% year-over-year, from $3.17M to $3.83M.
- What is the long-term trend for CareDx's reportable segment — research materials and clinical trials expense?
- Over 3 years (2022 to 2025), CareDx's reportable segment — research materials and clinical trials expense has grown at a -16.4% compound annual growth rate (CAGR), from $17.45M to $10.2M.
- What does reportable segment — research materials and clinical trials expense mean?
- Refers to the direct costs associated with conducting clinical studies and procuring materials necessary for the development and validation of new diagnostic solutions. This investment reflects the company's commitment to innovation and the long-term pipeline of its precision medicine portfolio.